SIGNIFICACIÓN BIOLÓGICA Y MARCADORES PRONÓSTICOS DE LA LEUCEMIA LINFÁTICA CRÓNICA Y ENTIDADES RELACIONADAS
Dr. Emili Montserrat
Servicio de Hematología. Hospital Clínic i Provincial. Barcelona.
Adaptación realizada por el Dr. Josep Gumà Padró.
Servei de Oncologia. Hospital St. Joan de Reus.
BIBLIOGRAFÍA
1. Galton DAG: The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J 1966; 94: 1005-1010.
2. Dameshek W: Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood 1967; 29: 566-584.
3. Rozman C (editor): Chronic lymphocytic leukaemia and related disorders. Baillière's Clin Haematol 1993; 6: 757-919.
4. Faguet GB: Chronic lymphocytic leukemia: an updated review. J Clin Oncol 1994; 12: 1974-1990.
5. Gale RP, Caligaris-Cappio F, Dighiero G et al (International Workshop on Chronic Lymphocytic Leukemia): Recent progress in chronic lymphocytic leukemia. Leukemia 1994; 8: 1610-1614.
6. Cheson BD: Chronic lymphocytic leukemia and hairy-cell leukemia. Curr Opin Haematol 1994; 1: 268-277 & B91-B93.
7. O'Brien S, del Giglio A, Keating MJ: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85: 307-318.
8. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-1057.
9. Montserrat E, Bosch F, Rozman C: Chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy. Ann Oncol 1997; en prensa.
10. Finch SC, Linet MS: Chronic leukaemias. Baillière's Clin Haematol 1992; 5: 27-56.
11. Nishiyama H, Mokuno J, Inoue T: Relative frequency and mortality rate of various types of leukemia in Japan. Jap J Cancer Res 1969; 60: 71-81.
12. Bernard SM, Cartwright RA, Bird CC et al: Aetiologic factors in lymphoid malignancies: a case control epidemiological study. Leukemia Res 1984; 8: 681-689.
13. Neuland CY, Blattner, Mann DL et al: Familial chronic lymphocytic leukemia. J Natl Cancer Inst 1983; 71: 1143-1150.
14. Blattner WA, Dean JH, Fraumeni JF: Familial lymphoproliferative malignancy: clinical and laboratory follow-up. Ann Intern Med 1979; 90: 943-944.
15. Cuttner J: Increased incidence of hematologic malignancies in first-degree relatives of patients with chronic lymphocytic leukemia. Cancer Invest 1992; 10: 103-109.
16. Caligaris-Cappio F: B-chronic lymphocytic leukemia: A malignancy of anti-self B cells. Blood 1996; 87: 2615-2620.
17. Pinto A, Vecchio LD, Carbone A et al: Expression of myelomonocytic antigens is associated with unfavorable clinico-prognostic factors in B-cell chronic lymphocytic leukemia. Ann Oncol 1991; 2: 107-113.
18. Polliack A, Rabinowitz R, Leizerowitz R et al: Myelomonocytic antigens are rarely expressed on B-lymphocytic leukemia cells. Leuk Lymphoma 1993; 9: 125-131.
19. Agee JF, Garver FA, Faguet GB: An antigen common to chronic lymphocytic and hairy-cell leukemia cells not shared by normal lymphocytes or by other leukemic cells. Blood 1986; 68: 62-68.
20. Zomas AP, Matutes E, Morilla R et al: Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia 1996; 10: 1966-1970.
21. Sonneveld P, Nooter K, Burghouts JTM et al: High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood 1992; 79: 1496-1500.
22. Wulf G, Kluding H, Ho AD et al: Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and Northern Blot analysis. Leuk Res 1994; 18: 475-484.
23. Möller P, Eichelmann A, Koretz K, Mechtersheimer G: Adhesion molecules VLA-1 to VLA-6 define discrete stages of peripheral B lymphocyte development and characterize different types of B cell neoplasia. Leukemia 1992; 6: 256-264.
24. Baldini L, Cro L, Calori R et al: Differential expression of very late activation antigen-3 (VLA-3)/VLA-4 in B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia. Blood 1992; 79: 2688-2693.
25. Woessner S, Asensio A, Florensa L et al:: Expression of lymphocyte function-associated antigen (LFA)-1 in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1994; 13: 457-461.
26. Juliusson G, Oscier DG, Fitchett M et al: Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720-724.
27. Juliusson G, Gahrton G: Cytogenetics in CLL and related disorders. Baillière's Clin Haematol 1993; 6: 821-848.
28. Pérez Losada A, Wessman M, Tiainen M et al: Trisomy 12 in chronic lymphocytic leukemia: An interphase cytogenetic study. Blood 1991; 78: 775-779.
29. Criel A, Wlodarska I, Meeus P et al: Trisomy 12 is uncommon in typical chronic lymphocytic leukemias. Br J Haematol 1994; 87: 523-528.
30 Hernandez JM, Mecucci C, Criel A et al: Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic criteria. Leukemia 1995; 9: 2140-2146.
31. Woessner S, Solé F, Pérez-Losada A et al: Trisomy 12 is a rare cytogenetic finding in typical chronic lymphocytic leukemia. Leuk Res 1996; 20: 369-374.
32. Stilgenbauer S, Döhner H, Bulgay-Mörschel M et al: High frequency of monoallelic retinoblastoma gene deletions in B-cell chronic lymphoid leukemia shown by interphase cytogenetics. Blood 1993; 81: 2118-2124.
33. Liu Y, Szekely L, Grander D, Soderhall S et al:: Chronic lymphocytic leukemia cells with allelic deletion at 13q14 commonly have one intact RB1 gene: Evidence for a role of an adjacent locus. Proc Natl Acad Sci USA 1993; 90: 8697-
34. Chapman RM, Corcoran MM, Gardiner A et al: Frequent homozygous deletions of the D13S25 locus in chromosome region 13q14 defines the location of a gene critical in leukemogenesis in chronic lymphocytic leukemia. Oncogene 1994; 9: 1289-....
35. Offit K, Louie DC, Parsa NZ et al: Clinical and morphological features of B-cell small lymphocytic lymphoma with del(6)(q21q23) Blood 1994; 83: 2611-2618.
36. Oscier D, Fitchett M, Herbert T, Lambert R: Karyotypic evolution in B-cell chronic lymphocytic leukemia. Gene Chromosome Canc 1991; 3: 16-20.
37. Nowell PC, Moreau L, Growney P, Besa EC: Karyotypic stability in chronic B-cell leukaemia. Cancer Genet Cytogenet 1988; 33: 155-160.
38. Fegan C, Robinson H, Thompson P et al: Karyotypic evolution in CLL: identification of a new subgroup of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995; 9: 2003-2008.
39. Rechavi G, Katzir N, Brok-Simoni F et al: A search for bcl1, bcl2, and c-myc oncogene rearrangements in chronic lymphocytic leukemia. Leukemia 1989; 3: 57-60.
40. Ohno H, Doi S, Yabumoto K et al: Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia. Leukemia 1993; 7: 2057-2063.
41. van Krieken JHJM, McKeithan TW, Raghoebier S et al: Chromosomal translocation t(14;19) as indicated by bcl-3 rearrangement is a rare phenomenon in non-Hodgkin's lymphoma and chronic lymphocytic leukemia; a molecular genetic analysis of 176 cases. Leukemia 1990; 4: 811-812.
42. Hawthorn LA, Chapman R, Oscier D et al: The consistent 13q14 translocation breakpoint seen in chronic B-cell leukemia (BCLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene. Oncogene 1993; 8: 1415-1419.
43. Brown AG, Ross FM, Dunne EM et al: Evidence for a new tumour suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. Nature Genetics 1993; 3: 67-72.
44. Bullrich F, Veronese ML, Kitada S et al: Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. Blood 1996; 88: 3109-3115.
45. Adachi M, Cossman J, Longo D et al: Variant translocation of the bcl-2 gene to immunoglobulin l light chain in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1989; 86: 2771-2774.
46. Thomas A, El Rouby S, Reed JS et al: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996; 12: 1055-1062.
47. McConckey DJ, Chandra J, Wright S et al: Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996; 156: 2624-2630.
48 Kay NE, Ranheim EA, Peterson LC: Tumor suppressor genes and clonal evolution in B-CLL. Leuk Lymphoma 1995; 18: 41-49.
49. Aoki H, Takishita M, Kosaka M, Saito S: Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström’s macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter’s syndrome but not in common CLL. Blood 1995; 85: 1913-1919.
50. Molica S: Infections in chronic lymphocytic leukemia: risk factors and impact on survival, and treatment. Leuk Lymphoma 1994; 13: 203-214.
51. Bonvalet D, Foldes C, Civatte J: Cutaneous manifestations in chronic lymphocytic leukemia. J Dermatol Surg Oncol 1984; 10: 278-282.
52. Van de Casteele M, Verhoef GEG, Demuynck H et al: Hypercalcemia, monoclonal protein, and osteolytic bone lesions in chronic lymphocytic leukemia. Ann Hematol 1994; 69: 79-80.
53. López Guillermo A, Cervantes F, Bladé J et al: Central nervous system involvement demonstrated by immunological study in prolymphocytic variant of chronic lymphocytic leukemia. Acta Haematol 1989; 81: 109-111.
54. Van de Casteele M, Verhoef GEG, Demuynck H et al: Hypercalcemia, monoclonal protein, and osteolytic bone lesions in chronic lymphocytic leukemia. Ann Hematol 1994; 69: 79-80.
55. Seney FD, Federgreen WR, Stein H, Kashgarian M: A review of nephrotic syndrome associated with chronic lymphocytic leukemia. Arch Intern Med 1986; 146: 137-141.
56. Ribera JM, Viñolas N, Urbano Ispízua A et al: "Spontaneous" complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature. Blood Cells 1987; 12: 471-479.
57. Ho C-H, Chiang Y-M, Chong L-L et al: Development of chronic lymphocytic leukaemia in a case of Sjögren's syndrome with systemic lupus erythematosus. Scand J Haematol 1985; 35: 246-248.
58. Haubenstock A, Zalusky R: Autoimmune hyperthyroidism and thrombocytopenia developing in a patient with chronic lymphocytic leukemia. Am J Hematol 1985; 19: 281-283.
59. Kipps TJ, Carson DA: Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993; 81: 2475-2487.
60. Hamblin TJ, Oscier DG, Young BJ: Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol 1986; 39: 713-716.
61. Rozman C, Montserrat E, Viñolas N: Serum immunoglobulins in B-chronic lymphocytic leukaemia. Natural history and prognostic significance. Cancer 1988; 61: 279-283.
62. Pangalis GA, Moutsdopoulos HM, Papadopoulos NM et al: Monoclonal and oligoclonal immunoglobulins in the serum of patients with B-chronic lymphocytic leukemia. Acta Haematol 1988; 80: 23-27.
63. Beaume A, Brizard A, Dreyfus B, Preud'homme JL: High incidence of serum monoclonal IgS detected by a sensitive immunoblotting technique in B-cell chronic lymphocytic leukemia. Blood 1994; 84: 1216-1219.
64. Richter MN: Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukaemia. Am J Pathol 1928; 4: 285-292.
65. Robertson LE, Pugh W, O'Brien S et al: Richter's syndrome: a report on 39 patients. J Clin Oncol 1993; 11: 1985-1989.
66. Cherepakhin V, Baird SM, Meisenholder GW, Kipps TJ: Common clonal origin of chronic lymphocytic leukemia and high-grade lymphoma of Richter's syndrome. Blood 1993; 82: 3141-3147.
67. Galton DAG, Goldman JM, Wiltshaw E, et al: Prolymphocytic leukaemia. Br J Haematol 1974; 27: 7-23.
68. Enno A, Catovsky D, O'Brien M et al: Prolymphocytoid" transformation of chronic lymphocytic leukemia. Br J Haematol 1979; 41: 9-18.
69. Melo JV, Catovsky D, Galton DAG: The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986; 63: 377-387.
70. Brouet JCV, Fermand JP, Laurent G et al: The association of chronic lymphocytic leukaemia and multiple myeloma: A study of eleven patients. Br J Haematol 1985; 59: 55-66.
71. Zarrabi MH, Grünwald HW, Rosner F: Chronic lymphocytic leukemia terminating in acute leukemia. Arch Intern Med 1977; 137: 1059-1064.
72. Choi H, Keller RH: Coexistence of chronic lymphocytic leukemia and Hodgkin's disease. Cancer 1981; 48: 48-57.
73. Papayanis AG, Stathakis NE, Kyrkoy K et al: Primary acquired sideroblastic anemia associated with chronic lymphocytic leukaemia. Br J Haematol 1974; 28: 125-129.
74. Jacobsen N, Theilade K, Videbaek A: Two additional cases of coexisting polycythaemia vera and chronic lymphocytic leukaemia. Scand J Haematol 1982; 29: 405-410.
75. Schreiber ZA, Axelrod MR, Abebe LS: Coexistence of chronic myelogenous leukemia and chronic lymphocytic leukemia. Cancer 1984; 54: 697-701.
76. Greene MH, Hoover RN, Fraumeni JF: Subsequent cancer in patients with chronic lymphocytic leukemia. A possible immunologic mechanism. J Natl Cancer Inst 1978; 61: 337-340.
77. Manusow D, Weinerman BH: Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232: 267-269.
78. Santoro A, Rilke F, Franchi F, Monfardini S: Primary malignant neoplasms associated with chronic lymphocytic leukemia. Tumori 1980; 66: 431-438.
79. López-Guillermo A, Reverter JC, Cervantes F et al: Neoplasias asociadas a la leucemia linfática crónica. Incidencia y características en una serie de 232 pacientes. Med Clin (Barc) 1989; 93: 681-683.
80. Travis LB, Curtis RE, Hankey BF, Fraumeni JF: Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 1992; 84: 1422-1427.
81. International Workshop on Chronic Lymphocytic Leukemia: Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann Intern Med 1989; 110: 236-238.
82. Cheson BD, Bennett JM, Grever M et al: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
83. Litz CE, Brunning RD: Chronic lymphoproliferative disorders: classification and diagnosis. Baillière's Clin Haematol 1993; 6: 767-783.
84. Harris NL, Jaffe E, Stein H et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
85. Bennett JM, Catovsky D, Daniel MT et al: Proposals for the classification of chronic (mature) B and T lymphoid leukemias. J Clin Pathol 1989; 42: 567-584.
86. Montserrat E, Rozman C: Chronic lymphocytic leukaemia: prognostic factors and natural history. Baillière's Clin Haematol 1993; 6: 849-866.
87. Rai KR, Sawitsky A, Cronkite EP et al: Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
88. Binet JL, Auquier A, Dighiero G et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
89. Montserrat E, Viñolas N, Reverter JC, Rozman C: Natural history of chronic lymphocytic leukemia: on the progression and prognosis of early clinical stages. Nouv Rev Franç Hematol 1988; 30: 359-361.
90. Ellims PH, Gan TE, van der Weyden MB: Thymidine kinase isoenzymes in chronic lymphocytic leukaemia. Br J Haematol 1981; 49: 479-481.
91. Reinisch W, Willheim M, Hilgarth M et al: Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994; 12: 2146-2152.
92. Lavabre-Bertrand T, Exbrayat C, Bourquard P et al: CD23 antigen density is related to serum gamma globulin level, bone marrow reticulin pattern, and treatment in B chronic lymphocytic leukemia. Leuk Lymphoma 1994; 13: 89-94.
93. Keating MJ, Lerner S, Kantarjian H et al: The serum b2-microglobulin (b2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) (abstract). Blood 1995; 86: 606a.
94. Sparrow RL, Hall FJ, Siregar H, van der Weyden MB: Common expression of the multidrug resistance marker p-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leuk Res 1993; 17: 941-947.
95. El Rouby S, Thomas A, Costin D et al: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452-3459.
96. Catovsky D, Fooks J, Richards S (a report from the MRC CLL 1 trial): Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex, and response to treatment in survival. Br J Haematol 1989; 72: 141-149.
97. Tallman MS, Hakimian D: Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463-2474.
98. O'Brien S, Kantarjian H, Beran M et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-1700.
99. Keating MJ, O'Brien S, Kantarjian H et al: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-2884.
100. Juliusson G, Liliemark J: High complete remission rate from 2-chloro-2'deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11: 679-689.
101. Delannoy A, Martiat P, Gala JL et al: 2-chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9: 1130-1135.
102. Saven A: The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Semin Hematol 1996; 33 (suppl 1): 28-33.
103. Majumdar G, Singh AK: Role of splenectomy in chronic lymphocytic leukaemia with massive splenomegaly and cytopenia. Leuk Lymphoma 1992; 7: 131-134.
104. Aabo K, Walbom-Jorgensen S: Spleen irradiation in chronic lymphocytic leukemia (CLL): palliation in patients unfit for splenectomy. Am J Hematol 1985; 19: 177-180.
105. Chikkappa G, Pasquale D, Zarrabi MH et al: Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia. Am J Hematol 1992; 41: 5-12.
106. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia: Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988; 319: 902-907.
107. Chapel H, Dicato M, Gamm H et al: Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol 1994; 88: 209-212.
108. Jurlander J, Hartmann Geisler C, Hansen MM: Treatment of hypogamma-globulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 1994; 53: 114-118.
109. Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81-86.
110. Chapel H, Dicato M, Gamm H et al: Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol 1994; 88: 209-212.
111. Hollander AAMJ, Kluin-Nelemans HC et al: Correction of neutropenia associated with chronic lymphocytic leukemia following treatment with granulocyte-macrophage colony-stimulating factor. Ann Hematol 1991; 62: 32-34.
112. Pozlopoulos Ch, Panayiotidis P, Angelopoulos MK, Pangalis GA: Treatment of anaemia in B-chronic lymphocytic leukaemia (B-CLL) with recombinant human erythropoietin (r-HuEPO) (abstract). Br J Haematol 1994; 87 (suppl 1): 232.
113. Riddell S, Johnston JB, Bowman D et al: 2-deoxycoformycin (DCF) in chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia (abstract). Proc ASCO 1985; p:167.
114. Grever MR, Leiby JM, Kraut EH et al: Low dose deoxycoformycin in lymphoid malignancies. J Clin Oncol 1985; 3: 1196-1200.
115. O'Dwyer PJ, Wagner B, Leyland-Jones B et al: 2-deoxycoformycin (Pentostatin) for lymphoid malignancies. Ann Intern Med 1988; 108: 733-743.
116. Dillman RO, Mick R, McIntyre OR: Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 433-439.
117. Ho AD, Thaler J, Stryckmans P et al: Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 1990; 82: 1416-1420.
118. Dearden C, Catovsky D. Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 1990; 62: 4-5.
119. Grever MR, Kopecky KJ, Coltman CA et al: Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. N Rev Franç Hematol 1988; 30: 457-459.
120. Sorensen JM, Vena D, Fallavolita A et al: Treatment of refractory chronic lymphocytic leukemia (CLL) with fludarabine monophosphate (FAMP) under the group C protocol. Proc ASCO 1992; 11: 264a.
121. Zinzani PL, Lauria F, Rondelli D et al: Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur J Hematol 1993; 51: 93-97.
122. Montserrat E, López-Lorenzo JL, Manso F et al: Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia. The Spanish Group Experience. Leuk Lymphoma 1996; 21: 467-472.
123. The French Cooperative Group on CLL, Johnson S, Smith AG, Löffler H et al: Multicentre prospective randomised trial of fludarabine versus cyclophos-phamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 1996; 347: 1432-1438.
124. Rai KR, Peterson B, Elias L et al: A ramdomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG inter-group study (Abstract). Blood 1996; 88 (suppl 1): 141a.
125. Juliusson G, Christiansen I, Hansen MM et al: Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160-2166.
126. Anaissie E, Kontoyiannis DP, Kantarjian H et al: Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med 1992; 117: 466-469.
127. Spielberger RT, Stock W, Larson RA: Listeriosis after 2-chlorodeoxi-adenosine treatment (letter). N Engl J Med 1993; 328: 813-814.
128. Cheson BD: Infectious and immunosuppresive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-2448.
129. Bastion Y, Coiffier B, Dumontet C et al: Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 1992; 3: 171-173.
130. Di Raimondo F, Giustolisi R, Cacciola E et al: Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 1993; 11: 63-68.
131. Hurst PG, Habib MP, Garewall H et al: Pulmonary toxicity associated with fludarabine monophosphate. Invest New Drugs 1987; 5: 207-210.
132. Cervantes F, Salgado C, Montserrat E, Rozman C: Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis (letter). Lancet 1990; 2: 1130.
133. Frame JN, Dahut WL, Crowley S: Fludarabine and acute tumor lysis in chronic lymphocytic leukemia (letter). N Engl J Med 1992; 327: 1396.
134. Maung ZT, Wood AC, Jackson GH et al: Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1994; 88: 649-652.
135. Briz M, Cabrera R, Sanjuán I et al: Diagnosis of transfusion-associated graft versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 409-411.
136. Stickney DR, Foon KA: Biologic response modifiers: therapeutic approaches to lymphoproliferative diseases. Curr Opin Oncol 1992; 4: 847-855.
137. Grossbard ML, Press OW, Appelbaum FR et al: Monoclonal antibody-based therapies for leukemia and lymphoma. Blood 1992; 80: 863-878.
138. Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993; 362: 755-758.
139. Montserrat E, Villamor N, Urbano-Ispizua A et al: Alpha interferon in chronic lymphocytic leukaemia. Eur J Cancer 1991; 27 (suppl 4): 74-77.
140. Michallet M, Archimbaud E, Bandini G et al: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 1996; 124: 311-315.
141. Rabinowe SN, Soiffer RJ, Gribben JG et al:: Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366-1376.
142. Khouri IF, Keating MJ, Vriesendorp HM et al: Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J Clin Oncol 1994; 12: 748-758.
143. Mehta J, Powels R, Singhal S et al: Clinical and hematological response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft versus leukemia. Bone Marrow Transpl 1996; 17: 371-375.
144. Davi F, Maloum K, Michell A et al: High frequency of somatic mutations in the VH genes expressed in prolymphocytic leukemia. Blood 1996; 88: 3953-3961.
145. Brunning RD: T-prolymphocytic leukemia. Blood 1991; 78: 3111-3113.
146. Matutes E, Brito-Babapulle V, Swansbury J et al: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78: 3269-3274.
147. Melo J, Robinson DSF, Catovsky D: The differential diagnosis between chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders: morphological and immunological studies. In: Polliack A, Catovsky D, eds, Chronic Lymphocytic Leukemia, 1988; 85-103, Harwood Academic Publishers, Chur.
148. Hoyer JD, Ross CW, Li C-Y et al: True T-cell chronic lymphocytic leukemia: A morphologic and immunophenotypic study of 25 cases. Blood 1995; 86: 1163-1169.
149. Mercieca J, Matutes E, Dearden C et al: The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994; 12: 2588-2593.
150. Bouroncle BA, Wiseman BK, Doak CA: Leukemic reticuloendotheliosis. Blood 1958; 13: 609-629.
151. Catovsky D, Petit JE, Galton DAG et al: Leukaemic reticuloendotheliosis ("Hairy" Cell Leukemia). Br J Haematol 1974; 26: 9-27.
152. Cawley JC, Burnst GF, Hayhoe FGJ: A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res 1980; 4: 547-559.
153. Bosch F, Campo E, Jares P et al: Increased expression of the PRAD-1/ CCND1 gene in hairy cell leukaemia. Br J Haematol 1995; 91: 1025-1030.
154. Schmid M, Porzsolt F: Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leuk Lymphoma 1995; 17: 401-410.
155. Haglund U, Juliusson G, Stellan B, Gahrton G: Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions. Blood 1994; 83: 2637-2645.
156. Platanias LC, Golomb HM: Hairy cell leukaemia. Baillière's Clin Haematol 1993; 6: 887-898.
157. Frassoldati A, Lamparelli T, Federico M et al: Hairy cell leukemia: A clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Leuk Lymphoma 1994; 13: 307-316.
158. Mercieca J, Matutes E, Emmett E et al: 2-Chlorodeoxy-adenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol 1996; 93: 409-411.
159. Ambrosetti A, Nadali G, Vinante F et al: Soluble interleukin-2 receptor in hairy-cell leukemia: A reliable marker of the disease. Int J Clin Lab Res 1993; 23: 34-37.
160. Gollard R, Lee TC, Piro LD, Saven A: The optimal management of hairy cell leukemia. Drugs 1995; 49: 921-931.
161. Saven A, Piro LD: Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin. Ann Intern Med 1993; 119: 278-283.
162. Seymour JF, Kurzrock R, Freireich E, Estey EH: 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy-cell leukemia. Blood 1994; 83: 2906-2911.
163. Grever M, Kopecky K, Foucar MK et al; Randomized comparison of Pentostatin versus Interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 1995; 13: 974-982.
164. Juliusson G, Heldal D, Hippe E et al: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy-cell leukemia. J Clin Oncol 1995; 13: 989-995.
165. Juliusson G, Lenkei R, Tjonnfjord G et al: Low-dose cladribine for symptomatic hairy cell leukaemia. Br J Haematol 1995; 89: 637-639.
166. Wheaton S, Tallman MS, Hakimian D, Peterson L: Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosyne. Blood 1996; 87: 1556-1560.
167. Bain BJ, Catovsky D: The leukaemic phase of non-Hodgkin's lymphoma. J Clin Pathol 1995; 48: 189-193.
168. Kroft SH, Finn WG, Peterson LC: The pathology of the chronic lymphoid leukaemias. Blood Rev 1995; 9: 234-250.
169. Melo JV, Hedge U, Parreira A et al: Splenic B-cell lymphoma with circulating villous lymphocytes: differential diagnosis of B-cell leukaemias with large spleens. J Clin Pathol 1987; 40: 642-651.
170. Mulligan SP, Catovsky D: Splenic lymphoma with villous lymphocytes. Leuk Lymphoma 1992; 6: 97-105.
171. Dierlamm J, Pittaluga S, Wlodarska I et al: Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996; 87: 299-307.
172. Troussard X, Valensi F, Duchayne E et al: Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996; 93: 731-736.
173. Offit K, Louie DC, Parsa NZ et al: del(7)(q32) is associated with a subset of small lymphocytic lymphoma with plasmacytoid features. Blood 1995; 86: 2365-2370.
174. Iida S, Rao P, Nallasivam P et al: The t(9;14)(q13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves de PAX-5 gene. Blood 1996; 88: 4110-4117.
175. Weisenburger D, Armitage JO: Mantle cell lymphoma: an entity comes of age. Blood 1996; 87: 4483-4494.
176. Velders GA, Kluin-Nelemans JC, De Boer CJ et al: Mantle-cell lymphoma: A population-based clinical study. J Clin Oncol 1996; 14: 1269-1274.
177. Bosch F, Jares P, Campo E et al: PRAD-1/CYCLIN D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific markers of mantle cell lymphoma. Blood 1994; 84: 2726-2732.
178. Greiner TC, Moynihan MJ, Chan WC et al: p53 mutations in mantle cell lymphoma are associated with variant cytology and predict poor prognosis. Blood 1996; 87: 4302-4310.
179. Pinyol M, Hernandez L, Cazorla M et al: Deletions and loss of expression pf P16INK4a and P21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997; 89: 272-280.
180. Pombo de Oliveira MS, Jaffe ES, Catovsky D: Leukaemic phase of mantle zone (intermediate) lymphoma: its characterisation in 11 cases. J Clin Pathol 1989; 42: 962-972.
181. Pittaluga S, Wlodarska I, Stul MS et al: Mantle cell lymphoma: a clinico-pathological study of 55 cases. Histopathology 1995; 26: 17-24.
182. Resnitzky P, Matutes E, Hedges M et al: The ultraestructure of mantle-cell lymphoma and other B-cell disorders with translocation t(11;14)(q13;q32). Br J Haematol 1996; 94: 352-361.
183. Rozman M, Bosch F, Villamor N et al: Mantle-cell lymphoma (MCL) in leukemic phase ("MC leukemia"): A study of 14 cases. Blood, 1996; 88 (suppl 1): 225a, abstract no. 888.
184. Haas R, Brittinger G, Meusers P et al: Myeloablative therapy with blood stem cell transplantation is effective in mantle-cell lymphoma. Leukemia 1996; 10: 1975-1979.
185. Semenzato G, Zambello R, Starkebaum G et al: The lymphoproliferative disease of granular lymphocytes: Updated criteria for diagnosis. Blood 1997; 89: 256-260.
186. Loughran ThP Jr: Clonal diseases of large granular lymphocytes. Blood 1993; 82: 1-14.
187. Jaffe ES: Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87: 1207-1210.
188. Matutes E, Catovsky D: Mature T-cell leukemias and leukemia/lymphoma syndromes: Review of our experience in 175 cases. Leuk Lymphoma 1991; 4: 81-91.
189. Pellenz M, Zambello R, Semenzato G, Loughran ThP Jr: Detection of Epstein-Barr virus by PCR in lymphoproliferative disease of granular lymphocytes. Leuk Lymphoma 1996; 23: 371-374.
190. Gentile TC, Wener MH, Starkebaum G, Loughran ThP Jr: Humoral immune abnormalities in T-cell large granular lymphocyte leukemia. Leuk Lymphoma 1996; 23: 365-370.
191. Jakubowski A, Winton EF, Gencarelli A, Gabrilove J: Treatment of chronic neutropenia associated with large granular lymphocytosis with cyclosporine A and filgastrim. Am J Hematol 1995; 50: 288-291
192. Bible KC, Tefferi A: Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol 1996; 93: 406-408.
193. Sézary A, Bouvrain Y: Erythrodermie avec présence de cellules monstreuses dans derme et sang circulant. Bull Soc Fr Dermatol Syph 1938; 45: 254-260.
194. Diamandidou E, Cohen PhR, Kurzrock R: Mycosis fungoides and Sézary syndrome. Blood 1996; 88: 2385-2409.
195. Lorincz A: Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 1996; 347: 871-876.
196. Vonderheid EC, Sobel EL, Nowell PC et al: Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T-cell lymphoma. Blood 1985; 66: 358-366.
197. Limon J, Nedoszytko B, BrozeI et al: Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sézary syndrome. Cancer Genet Cytogenet 1995; 83: 75-81.
198. Kim YH, Bishop K, Varghese A, Hoppe RT: Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995; 131: 1003-1008.
199. Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 1995; 9: 1109-1116.
200. Kuzel TM, Roenigk HH Jr, Samuelson E et al: Effectiveness of interferon alfa-2a combined with phothotherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995; 13: 257-263.
201. Kuzel TM, Hurria A, Samuelson E et al: Phase II trial of 2-chlorodeoxyadenosine for the treatmet of cutaneous T-cell lymphoma. Blood 1996; 87: 906-911.
202. Takatsuki K, Uchiyama, Sagawa K, Yodoi J: Adult T cell leukemia in Japan. In: Seno S, Takaku F, Irino S, eds, Topics in Hematology, 1977; pp: 73-77. Excerpta Medica, Amsterdam.
203. Uchiyama T, Yodoi J, Sagawa K et al: Adult T cell leukemia: clinical and hematologic features in 16 cases. Blood 1977; 50: 481-492.
204. Poiesz BJ, Ruscetti FW, Gazdar AF et al: Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of patients with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-7419.
205. Catovsky D, Greaves MF, Rose M et al: Adult T-cell lymphoma in Blacks from the West Indies. Lancet 1982; I: 639-643.
206. Gurtsevicth V, Senjuta N, Pavlish O et al: Clinical, morphological and virological features of an HTLV-I positive case of ATL in a white man from the Caucasus. Leuk Res 1993; 17: 621-627.
207. Cunningham D, Gilchrist NG, Jack A et al: T-lymphoma associated with HTLV-I outside the Caribbean and Japan. Lancet 1985; II: 337-338.
208. Yamaguchi K, Takatsuki K: Adult T cell leukaemia-lymphoma. Baillière's Clin Haematol 1993; 6: 899-915.
209. Gill PS, Harrington W Jr, Kaplan MH et al: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332: 1744-1748.
210. Borg A, Yin JA, Johnson PR et al: Successful treatment of HTLV-I associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br J Haematol 1996; 94: 713-715.
[ÍNDICE]
[LEUCEMIA LINFÁTICA CRÓNICA]
[LEUCEMIA
PROLINFOCÍTICA]
[LEUCEMIA
DE CÉLULAS PELUDAS] [LINFOMA
ESPLÉNICO CON LINFOCITOS VELLOSOS]
Siguiente Conferencia »